Af­ter a ‘break­through’ be­gin­ning to 2020, lit­tle Aprea gets crushed by a PhI­II fail­ure

Boston-based biotech Aprea Ther­a­peu­tics $APRE start­ed the year with a promis­ing break­through ther­a­py des­ig­na­tion from the FDA for its lead p53 re­ac­ti­vat­ing pro­gram for eprene­tapopt. And it’s end­ing the year with a Phase III fail­ure for the drug.

Aprea re­port­ed out Mon­day morn­ing that the drug com­bined with azac­i­ti­dine failed to sig­nif­i­cant­ly out­per­form azac­i­ti­dine alone in TP53 mu­tant myelodys­plas­tic syn­dromes. And their stock price crum­bled un­der the rout that fol­lowed, drop­ping 73%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER